PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

Samankaltaisia teoksia

• 1093 CLN-617 combines IL-2 and IL-12 in a single molecule to optimally balance safety and efficacy upon intratumoral injection
  Tekijä: Naveen K Mehta, et al.
  Julkaistu: (2023-11-01)
• CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
  Tekijä: Naveen K Mehta, et al.
  Julkaistu: (2025-04-01)
• 1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
  Tekijä: Agapitos Patakas, et al.
  Julkaistu: (2023-11-01)
• PB1847: A PHASE 1 STUDY TO INVESTIGATE CLN-049, A FLT3/CD3 BISPECIFIC T CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
  Tekijä: Maher Abdul-Hay, et al.
  Julkaistu: (2023-08-01)
• CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
  Tekijä: Agapitos Patakas, et al.
  Julkaistu: (2023-08-01)